Non-muscle invasive bladder cancer is one of the most common cancers in the developed world, and although it is caught early in most patients, it has an uncomfortable habit of coming back. Standard treatment involves surgically removing visible tumours and then flushing the bladder with chemotherapy drugs such as mitomycin C, or with the live bacterium BCG, in an attempt to destroy any malignant cells left behind. Yet despite these efforts, a large proportion of patients experience recurrence, and some progress to muscle-invasive disease that requires far more aggressive therapy. Researchers at University Medical Center Utrecht in the Netherlands now report a strategy that could dramatically improve those odds, showing in laboratory models built directly from patient tumours that pairing intravesical chemotherapy with drugs that disable a key DNA repair enzyme can wipe out cancer cells that would otherwise survive and regrow.
The new study, published in the British Journal of Cancer, focuses on a kinase called ATR, short for ataxia telangiectasia and Rad3-related protein. ATR sits at the heart of the cellular response to replication stress, the potentially lethal situation in which the molecular machinery that copies DNA stalls or breaks down. When chemotherapy drugs such as mitomycin C damage DNA, dividing cells rely heavily on ATR signalling to pause the cell cycle, stabilise stalled replication forks and coordinate repair. Block ATR pharmacologically, and cells exposed to DNA-damaging agents lose their safety net: replication forks collapse, DNA double-strand breaks accumulate, and the cell is pushed toward catastrophe. This concept, often described as exploiting a vulnerability created by the tumour’s own dependence on DNA damage checkpoints, has already shown promise in clinical trials of ATR inhibitors such as berzosertib in combination with platinum chemotherapy for advanced solid tumours.
What makes the Utrecht study distinctive is its model system. Rather than relying on immortalised cancer cell lines grown in two dimensions, which often fail to capture the biology of real tumours, the team used patient-derived organoids, miniature three-dimensional tumour cultures grown from tissue of six patients with non-muscle invasive bladder cancer. Organoids preserve many of the genetic and molecular features of the original tumours, including the expression of urothelial carcinoma markers, making them a far more faithful testing ground for new drug combinations. The researchers confirmed that their organoid lines expressed characteristic bladder cancer markers, validating them as genuine representatives of the disease they were designed to model.
The experimental design cleverly mimicked clinical practice. In patients, mitomycin C is delivered directly into the bladder as an instillation that remains in contact with the tumour tissue for roughly one to two hours before being drained. The researchers therefore exposed the organoids to mitomycin C for just two hours, replicating the transient exposure that tumour cells experience in the bladder, and only afterwards did they add ATR inhibitors, which the cells encountered for a prolonged 72-hour period. Three clinically relevant ATR inhibitors were tested: berzosertib, ceralasertib and tuvusertib, all of which have entered clinical trials in various cancers. The team also examined combinations with gemcitabine and epirubicin, two further agents used in intravesical chemotherapy regimens, in one organoid line.
The results were striking. Organoids treated with mitomycin C alone, or with an ATR inhibitor alone, eventually recovered: when the researchers followed the cultures for six weeks after treatment, the surviving cells proliferated at rates similar to untreated controls, demonstrating that neither agent on its own could eliminate the tumour cell population. In sharp contrast, organoids that received the sequential combination of mitomycin C followed by an ATR inhibitor showed severely impaired viability, and crucially, this effect persisted throughout the six-week observation period. The combination did not merely slow the cancer cells down; it appeared to destroy their capacity to regrow, which is precisely the property needed for a therapy intended to prevent recurrence after tumour resection.
Delving into the mechanism, the researchers showed that berzosertib potently suppressed the ATR signalling that mitomycin C normally triggers. DNA damage induced by the chemotherapy was marked by phosphorylated H2AX, a well-established molecular beacon of DNA double-strand breaks, and blocking ATR prevented the checkpoint response that would normally allow cells to survive this damage. Consistent with catastrophic, irreparable DNA damage, the combination treatment drove the organoid cells into apoptosis, the controlled programme of cell death. Quantitative analysis of the drug interaction using synergy scoring frameworks confirmed that the effect was genuinely synergistic rather than merely additive, meaning the two drugs together killed far more cells than would be predicted from their individual activities.
The implications for patients are considerable. Recurrence after intravesical therapy remains the central clinical challenge in non-muscle invasive bladder cancer, driving repeated surgeries, lifelong surveillance and, in a substantial minority of cases, progression to life-threatening muscle-invasive disease. The economic burden of bladder cancer across Europe is among the highest of any malignancy, largely because of the intensity of monitoring and repeat treatment that recurrence entails. A regimen that converts transient chemotherapy exposure into durable eradication of residual tumour cells could reduce recurrence rates, spare patients repeated interventions and delay or prevent progression. Because ATR inhibitors such as berzosertib, ceralasertib and tuvusertib are already in clinical development, the path from laboratory finding to clinical testing is shorter than for an entirely novel drug class.
There are important caveats. The study is preclinical, conducted in organoids rather than in patients, and although organoids are among the most clinically predictive laboratory models available, they cannot fully reproduce the immune system, the bladder wall architecture or the complex urine environment that shapes drug activity in vivo. The number of organoid lines tested, six for the mitomycin C combinations, is modest, and the gemcitabine and epirubicin experiments were limited to a single line, so the generality of the synergy across the molecular diversity of bladder cancer remains to be established. Questions also remain about the optimal sequencing, dosing and delivery of ATR inhibitors in the bladder, and about whether systemic administration would be needed or whether the inhibitors could themselves be delivered intravesically to limit side effects.
Nevertheless, the study provides a compelling proof of principle that the DNA damage response is a druggable Achilles heel of non-muscle invasive bladder cancer, and it establishes patient-derived organoids as a practical platform for optimising intravesical combination therapies before they are tested in the clinic. The findings build on a growing body of evidence that ATR inhibition sensitises bladder tumours to DNA-targeted agents, including earlier work showing enhanced cisplatin and gemcitabine activity in bladder cancer cell lines and clinical trial data combining berzosertib with platinum chemotherapy in advanced urothelial carcinoma. If the synergy observed in these miniature tumours translates to patients, the humble bladder instillation, a treatment whose basic design has changed little in decades, could be transformed into a precision strike that leaves behind not just damaged cancer cells, but none at all.
Subject of Research: Combining ATR kinase inhibitors with intravesical chemotherapy to prevent recurrence in non-muscle invasive bladder cancer, tested in patient-derived organoids.
Article Title: ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids
Article References: Zuidema, A., Nijland, L., van Megesen, K., Vosjan, M. M., Viergever, B. J., Kranenburg, O., & Meijer, R. P. (2026). ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03581-0
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03581-0
Keywords: bladder cancer, ATR inhibitors, mitomycin C, patient-derived organoids, DNA damage response, non-muscle invasive bladder cancer, berzosertib, ceralasertib, tuvusertib, intravesical chemotherapy, drug synergy, cancer recurrence
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 12, 2026). ATR Inhibitors Supercharge Bladder Cancer Chemotherapy in Patient-Derived Organoids. Scienmag. https://scienmag.com/atr-inhibitors-supercharge-bladder-cancer-chemotherapy-in-patient-derived-organoids/
Nathaniel Bowman. “ATR Inhibitors Supercharge Bladder Cancer Chemotherapy in Patient-Derived Organoids.” Scienmag, 12 September 2026, https://scienmag.com/atr-inhibitors-supercharge-bladder-cancer-chemotherapy-in-patient-derived-organoids/. Accessed 12 September 2026.
Nathaniel Bowman. “ATR Inhibitors Supercharge Bladder Cancer Chemotherapy in Patient-Derived Organoids.” Scienmag. September 12, 2026. https://scienmag.com/atr-inhibitors-supercharge-bladder-cancer-chemotherapy-in-patient-derived-organoids/
Copy citation Download RIS
Tags: ATR inhibitorsATR kinase inhibitorsberzosertibbladder cancerbladder cancer recurrence preventionbladder cancer treatmentcancer cell survival mechanismscancer recurrenceceralasertibcombination therapy for bladder cancerDNA damage responseDNA repair enzyme targetingdrug synergyimproving bladder cancer chemotherapy outcomesintravesical chemotherapyintravesical chemotherapy enhancementmitomycin CNon-Muscle Invasive Bladder Cancerpatient-derived bladder cancer organoidspatient-derived organoidspersonalized bladder cancer modelstuvusertib
